Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 6;492(7427):108-12.
doi: 10.1038/nature11606. Epub 2012 Oct 10.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T McCabe  1 , Heidi M Ott, Gopinath Ganji, Susan Korenchuk, Christine Thompson, Glenn S Van Aller, Yan Liu, Alan P Graves, Anthony Della Pietra 3rd, Elsie Diaz, Louis V LaFrance, Mark Mellinger, Celine Duquenne, Xinrong Tian, Ryan G Kruger, Charles F McHugh, Martin Brandt, William H Miller, Dashyant Dhanak, Sharad K Verma, Peter J Tummino, Caretha L Creasy
Affiliations

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T McCabe et al. Nature. .

Abstract

In eukaryotes, post-translational modification of histones is critical for regulation of chromatin structure and gene expression. EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27). EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumour types. Additionally, somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The Y641 residue is the most frequently mutated residue, with up to 22% of germinal centre B-cell DLBCL and follicular lymphoma harbouring mutations at this site. These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes. However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas. Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice. Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. PLoS One. 2011;6(12):e28585 - PubMed
    1. Genome Biol. 2009;10(3):R25 - PubMed
    1. BMC Cancer. 2010 Oct 04;10:524 - PubMed
    1. FEBS Lett. 2011 Oct 3;585(19):3011-4 - PubMed
    1. Trends Biochem Sci. 2003 Jun;28(6):329-35 - PubMed

MeSH terms

Associated data

LinkOut - more resources

-